Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 16/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 14/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.73 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.73 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.73 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.73 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.73 |
| ▸ | UBA1 | P22314 | 1/20 | 0.73 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10314975 | 1.00 | HDAC1 (0.73) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL10314995 | 1.00 | HDAC1 (0.73) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL20156678 | 0.93 | HDAC1 (0.66) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL19871343 | 0.89 | HDAC3 (0.60) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL10315071 | 0.89 | HDAC3 (0.60) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL18495065 | 0.87 | HDAC1 (0.73) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL19871344 | 0.87 | HDAC1 (0.73) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL10315049 | 0.87 | HDAC1 (0.73) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL19114158 | 0.86 | HDAC1 (0.81) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL22810232 | 0.86 | HDAC1 (0.81) | HDAC1HDAC3HDAC2HDAC6HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044376-A1 | Method for Preparing Largazole Analogs and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-9186402-B2 | Method for preparing largazole analogs and uses thereof | Colorado State University Research University (US) | 2015-11-17 | — | — | US | disclosed |
| US-8513290-B2 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120264794-A1 | Method for Preparing Largazole Analogs and Uses Thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264794-A1 | Method for Preparing Largazole Analogs and Uses Thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8217076-B2 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217076-B2 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-20100029731-A1 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029731-A1 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010009334-A1 | METHOD FOR PREPARING LARGAZOLE ANALOGS AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029731-A1 | Method for preparing largazole analogs and uses thereof | CYP51A1, ADPRS, LPXN | HDAC1 355/4885HDAC3 114/4885HDAC2 362/4885 |
| US-20120264794-A1 | Method for Preparing Largazole Analogs and Uses Thereof | CYP51A1, ADPRS, LPXN | HDAC1 355/4885HDAC3 114/4885HDAC2 362/4885 |
| US-20180044376-A1 | Method for Preparing Largazole Analogs and Uses Thereof | CYP51A1, ADPRS, LPXN | HDAC1 355/4885HDAC3 114/4885HDAC2 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.